Updates from ASCO
ASCO has urged CMS to delay the October 1, 2026, launch of the GLOBE drug pricing model until the administration can better evaluate its potential impact on oncology practices. While supporting lower patient costs, the association remains concerned that the new benchmark could unintentionally restrict access to critical cancer care.
READ MORE
Molecular Inference–Based Deep Learning Assesses CNS Tumor Diagnosis: The accuracy of a hierarchical molecular inference–based deep-learning system, Neuropath-AI, was tested in central nervous system tumor diagnosis and classifications in a retrospective study. ASCO to Update Guideline for Multiple Myeloma.
READ MORE
Corporate Member News
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma.
READ MORE
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line.
READ MORE
